Nanotherapeutics was founded in 1999 as an integrated biopharmaceutical company with a focus on development and manufacturing and having expertise in:
- Preclinical and clinical development
- Formulation optimization
- cGMP manufacturing of biopharmaceuticals
- Quality control testing
The Company also has several proprietary platform technologies that are used in the production of biologic products including proteins, monoclonal antibodies and vaccines.
On March 30, 2013 the Department of Defense (DoD) awarded Nanotherapeutics and its team of partners and collaborators, a contract to provide all the core services necessary to establish a Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) capability dedicated to meet the specific needs of the DoD.
Today, Nanotherapeutics is well on the way to becoming a leading Contract Development and Manufacturing Organization (CDMO) serving both commercial and government customers in its U.S.-based 183,000 square foot, state of the art, single-use, multi-purpose-multi-product, biosafety containment level 3 (BSL-3) capable facility. The Company provides expertise from preclinical through FDA licensure in a variety of production platforms, including microbial and mammalian cell culture. The Company also owns a second, Czech Republic-based, 165,000 square foot, 6,000-liter capacity BSL-3 facility for manufacturing vaccines using its proprietary Vero cell platform.